PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 results Solid performance with 22% growth of oncology cartridge revenue, a 40% gross margin on product sales and a 20% improvement in EBITDA to EUR -14.5mOper
PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND.
PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION18 July 2023, 7:00 AM CEST Biocartis appoints George Cardoza as new CFO and Head of Service Delivery George Cardoza appointed as Biocartis’ new Chief Financial Officer and Head of Service Delivery.Announced operational reorganization and cost reduction program progressing according to plan. Mechelen, Belgium, 18 July 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BC
PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION18 July 2023, 7:00 AM CEST Biocartis appoints George Cardoza as new CFO and Head of Service Delivery George Cardoza appointed as.
PRESS RELEASE: REGULATED INFORMATION12 May 2023, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 12 May 2023 Mechelen, Belgium, 12 May 2023 – Biocartis Group NV. | May 12, 2023